EP Patent

EP1877060A2 — Therapeutic bifunctional compounds

Assigned to University of Colorado Denver · Expires 2008-01-16 · 18y expired

What this patent protects

The invention generally relates to systems and methods for treating inflammatory and proliferative diseases, enabling treatment of MDR tumor cells by using a bifunctional compound that inhibits both fatty acid metabolism and glycolysis. Thus, the invention links a fatty acid meta…

USPTO Abstract

The invention generally relates to systems and methods for treating inflammatory and proliferative diseases, enabling treatment of MDR tumor cells by using a bifunctional compound that inhibits both fatty acid metabolism and glycolysis. Thus, the invention links a fatty acid metabolism inhibitor to a glycolysis inhibitor. More particularly, the invention provides novel bifunctional compounds that link a moiety having the functionality of an oxirane carboxylic acid compound to a moiety having the functionality a glucose derivative. In specific embodiments, the invention provides a bifunctional compound that links a moiety having the functionality of etomoxir to a moiety having the functionality of 2-deoxy-D-glucose.

Drugs covered by this patent

Patent Metadata

Patent number
EP1877060A2
Jurisdiction
EP
Classification
Expires
2008-01-16
Drug substance claim
No
Drug product claim
No
Assignee
University of Colorado Denver
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.